Your session is about to expire
← Back to Search
Yeast Fermentate
Effects of a Yeast Fermentate (EpiCor) Supplement on Cold or Flu Symptoms in Healthy Children
N/A
Waitlist Available
Led By David Crowley, MD
Research Sponsored by Cargill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 42 and 84 days
Summary
This trial tests if taking EpiCor daily for about three months can reduce cold or flu symptoms in children aged 4-12 who go to school or daycare. EpiCor is a supplement that may help boost the immune system.
Eligible Conditions
- Respiratory Symptoms
- Breathing difficulties
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 42 and 84 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 42 and 84 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of cold or flu symptoms
Secondary study objectives
Duration of cold or flu symptoms
Incidence on cold or flu symptoms from baseline to day 42
Number of days prior to first cold or flu symptoms
+10 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: EpiCorExperimental Treatment1 Intervention
500 mg EpiCor given as two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.
Group II: PlaceboPlacebo Group1 Intervention
Two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EpiCor
2015
N/A
~340
Find a Location
Who is running the clinical trial?
CargillLead Sponsor
27 Previous Clinical Trials
2,975 Total Patients Enrolled
KGK Science Inc.Industry Sponsor
79 Previous Clinical Trials
5,934 Total Patients Enrolled
David Crowley, MDPrincipal InvestigatorKGK Science
37 Previous Clinical Trials
2,567 Total Patients Enrolled